Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for Neurocognitive Deficits in High Risk Obese Patients
NCT06171152Phase 1Suspended
- Sponsor
- University of Chicago
- Start
- Jan 2024
- Primary completion
- Jun 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of liraglutide in cognitive impairment (2 arms), sponsored by University of Chicago. Primary endpoint: Serum Brain Derived Neurotrophic Factor at 8 weeks. Started Jan 2024; status: suspended.
02
Drugs
03
Conditions
cognitive impairment
Beyond the preview
Go deeper on NCT06171152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06171152.